Skip to main content

Table 1 Patients` characteristics and treatment response

From: Erenumab in highly therapy-refractory migraine patients: First German real-world evidence

A) Episodic migraine (n=26)
Age, y 52.9 (SD 9.1) Sex, female : male 23 : 3
  Before treatment, d After 3 month, d P-value Change from baseline, d 50% response, %
MMD (SD) 9.42 (2.91) 5.99 (5.43) < 0.001 -3.43 (SE 1.26) 57.7
MHD (SD) 10.40 (2.47) 7.06 (5.46) 0.001 -3.33 (SE 1.17) 46.2
AMD (SD) 10.22 (4.69) 5.74 (5.07) <0.001 -4.48 (SE 1.27) 61.5
B) Chronic migraine (n=74)
Age, y 45.8 (SD 12.9) Sex, female : male 59 : 15
MOH (before treatment), n 49 MOH (after 3 month), n 26
  Before treatment, d After 3 month, d P-value Change from baseline, d 50% response, %
MMD (SD) 15.69 (6.64) 10.97 (7.81) <0.001 -4.72 (SE 0.87) 41.9
MHD (SD) 21.27 (5.5) 15.8 (8.9) <0.001 -5.47 (SE 0.86) 32.4
AMD (SD) 11.62 (6.14) 8.86 (5.97) <0.001 -2.76 (SE 0.83) 27.0
  1. Data before treatment reflect the 3 months before start of erenumab treatment. (MMD monthly migraine days, MHD monthly headache days, AMD monthly days of intake of acute migraine medication, SD standard deviation, SE standard error, y years, d days)